Embecta (NASDAQ:EMBC) Issues Quarterly Earnings Results

Embecta (NASDAQ:EMBC) posted its quarterly earnings results on Tuesday. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15), FiscalAI reports. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. During the same quarter last year, the firm earned $0.70 EPS. The company’s revenue was down 14.4% on a year-over-year basis. Embecta updated its FY 2026 guidance to 1.550-1.75 EPS.

Here are the key takeaways from Embecta’s conference call:

• The quarter missed expectations with Q2 revenue of approximately $222 million (down 14.4% y/y) and full‑year fiscal 2026 revenue guidance cut to $1.015B–$1.035B (organic midpoint ~ $995M), with ~70% of the ~$75M guidance reduction driven by pen needles and much of the share loss concentrated at a single large U.S. customer.
• Profitability and cash outlook were materially revised — adjusted operating margin guidance lowered to 22.25%–23.25%, adjusted EPS to $1.55–$1.75 (from $2.80–$3.00), and free cash flow guidance cut to $95M–$105M (from $180M–$200M), with a higher adjusted tax rate and near‑term dilution from the pending acquisition contributing to the change.
• Embecta expects to close the Owen Mumford acquisition this month (upfront ~GBP100M, up to GBP50M earnouts), which adds the Aidaptus auto‑injector platform and should diversify the portfolio beyond insulin devices, contribute ~$30M in FY26 (4 months) and be accretive over time.
• Strategic execution on GLP‑1 and product portfolio progress continues — ~40% of identified GLP‑1 partners are in active negotiations or contracts, several partners launched co‑packed generics in India, and new market‑appropriate pen needles/syringes are advancing through regulatory submissions and selective commercial launches.
• Capital allocation was reshaped — the board authorized up to $100M in share repurchases, cut the quarterly dividend to $0.01 from $0.15, plans ~$150M of debt repayment in 2026, and has initiated a cost‑structure/organizational review to address the guidance shortfall.

Embecta Price Performance

Shares of NASDAQ:EMBC traded down $5.03 during trading on Tuesday, hitting $4.22. 2,298,421 shares of the company were exchanged, compared to its average volume of 805,221. The stock has a market capitalization of $249.67 million, a P/E ratio of 1.71 and a beta of 1.09. Embecta has a 12-month low of $4.33 and a 12-month high of $15.55. The firm’s 50 day moving average price is $9.26 and its 200-day moving average price is $11.27.

Institutional Trading of Embecta

Several institutional investors have recently modified their holdings of the stock. Brooklyn Investment Group lifted its position in shares of Embecta by 5.9% during the 4th quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock worth $234,000 after buying an additional 1,098 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after buying an additional 1,110 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Embecta by 1.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock worth $1,785,000 after buying an additional 1,520 shares during the last quarter. Finally, Larson Financial Group LLC lifted its position in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after buying an additional 1,574 shares during the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on EMBC shares. Mizuho lowered their price target on shares of Embecta from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Monday, April 13th. BTIG Research reiterated a “buy” rating and set a $25.00 price target on shares of Embecta in a report on Friday, February 6th. Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $18.50.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.